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risk of cancer development  [2] . The main clinical symp-
toms include diarrhea, abdominal pain and fever, and pa-
tients are prone to increased morbidity and reduced qual-
ity of life. Although CD and UC partly differ in their clin-
ical presentation and underlying pathophysiology, both 
entities are characterized by the dysfunction of three ma-
jor mechanisms: (i) the intestinal barrier, (ii) the innate 
and the adaptive immune system and their interconnec-
tion, and (iii) effects of non-immune cells such as fibro-
blasts and the endothelium of mucosal vessels. While 
function and impairment of the intestinal barrier only re-
cently moved in the focus of IBD research, the role of both 
the adaptive and innate immune system has been studied 
extensively and will be subject to this concise review.
 Innate Immune System 
 Unlike any other organ, the gastrointestinal tract faces 
a unique challenge: while the intestinal mucosa has to 
provide protection from pathogens such as bacteria, fun-
gi and viruses, it also has to tolerate beneficial commensal 
microbiota and physiological food-associated antigens. 
This ‘hyporeactive’ state has to be tightly regulated and 
seems to turn into immunologic ‘hyperreactivity’ in pa-
tients with IBD. The first barrier is constituted by a mucus 
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 Abstract 
 While barrier function and the effects of the intestinal micro-
biome have only recently moved into the focus of inflamma-
tory bowel disease research, the role of the innate and the 
adaptive immune system in these gastrointestinal disorders 
has extensively been studied. Although still not completely 
understood, the increasing knowledge about the immune 
system’s contribution to the pathophysiology of inflamma-
tory bowel diseases has led to new diagnostic and therapeu-
tic approaches. This review gives a compact overview on this 
important topic.  © 2013 S. Karger AG, Basel 
 Introduction 
 Crohn’s disease (CD) and ulcerative colitis (UC) are 
the two entities classically referred to as inflammatory 
bowel diseases (IBD)  [1] . Both CD and UC are character-
ized by a chronic and relapsing idiopathic inflammation 
of the gastrointestinal tract. Moreover, IBD is accompa-
nied by extraintestinal manifestations and an increased 
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layer consisting of different antimicrobial agents  [3] , 
which are secreted by goblet cells and Paneth cells. Al-
though not the focus of this review, these molecules and 
cell types seem to substantively contribute to the patho-
genesis of IBD  [4] . The innate immune system constitutes 
the first line of active immunologic defense. Various 
 receptors such as Toll-like receptors (TLR), nucleotide 
oligomerization domain (NOD)-like receptors, C-type 
lectin receptors (CLR) or retinoic acid-inducible gene 
(RIG-1)-like receptors (RLR) sense different microbial 
molecules called pathogen-associated molecular patterns 
(PAMP). These receptors are located on macrophages, 
dendritic cells (DCs) and other cells of the lamina propria 
to initiate an inflammatory response  [5] . Experimental 
models have shown some of these receptors to play an 
important role in IBD. For example, myeloid differentia-
tion factor 88 (MyD88), a TLR signaling adaptor protein, 
is indispensable for development of enterocolitis in an 
IL-10-absent and IL-12/23-p40-dysregulated environ-
ment  [6] . NF-κB deficiency leads to apoptosis of colonic 
epithelial cells and consecutive translocation of bacteria 
into the mucosa. Deficiency of the gene encoding the 
adaptor protein MyD88 prevents the development of in-
testinal inflammation, demonstrating that TLR activa-
tion by intestinal bacteria is essential for disease patho-
genesis an experimental model of colitis  [7] . Additionally, 
polymorphisms in the genes for these receptors have been 
associated with IBD  [8] .
 Macrophages are an integral part of the innate im-
mune system of the gastrointestinal tract  [9] . They clear 
luminal microbes that manage to overcome the intestinal 
barrier by phagocytosis. Intestinal macrophages are char-
acterized by the markers F4/80, CD115 and CD14, but 
lack CD103 expression  [10] . It has been shown that under 
healthy conditions, intestinal macrophages show pro-
found anergy and contribute to tissue homeostasis 
through downregulation of proinflammatory cytokines 
 [11, 12] . This attenuation mediates physiologic tolerance. 
In IBD, on the contrary, macrophages together with cir-
culating monocytes orchestrate an exaggerated immuno-
logic response. This is characterized by an increased ex-
pression of IL-12, IL-23 and TNF-α in vitro  [13] . Animal 
models further showed an important role of IL-10, which 
controls immune regulation and macrophage function 
 [14] . IL-10-deficient mice develop spontaneous colitis by 
shifting macrophage differentiation to a more proinflam-
matory subset. This can be rescued by macrophage deple-
tion  [15] .
 Apart from macrophages, DCs are the other key cell 
type of the innate immune system in the gastrointestinal 
tract. DCs are located in the lamina propria, especially in 
the Peyer’s patches and also in the mesenteric lymph 
nodes. Under healthy conditions, luminal antigens are 
presented to DCs by epithelial cells and microfold cells (M 
cells). It has been demonstrated that DCs even have den-
drites reaching between epithelial cells directly into the 
lumen  [16] . Upon activation, DCs migrate to the mesen-
teric lymph nodes to interact with B and T cells and thus 
provide a link between the innate and the adaptive im-
mune system. Moreover, DCs coordinate T-cell genera-
tion and differentiation. Under healthy conditions, they 
can induce regulatory T cells, which suppress the function 
of effector T cells  [14, 17] . In a proinflammatory setting 
with high levels of IL-1 and TNF-α, as can be found in pa-
tients with IBD, DC trafficking is enhanced and they or-
chestrate the T-cell response (either Th1, Th2 or Th17) 
 [18] . For example, in CD, increased IL-12 production of 
DCs leads to Th1-mediated inflammation  [16] .
 Adaptive Immune System 
 Apart from the innate immune system, the adaptive 
immune response and their interconnection play an im-
portant role under healthy and pathologic conditions. 
Cells of the adaptive immune system include T and B cells 
and their various subtypes, and can be found in the mu-
cosa-associated lymphoid tissues (MALT). The general 
hallmark of these cells are surface receptors whose struc-
tures derive from gene rearrangement. This leads to high 
specificity and enables an immunologic ‘memory’ func-
tion. Although the epithelial layer and the innate immune 
system constitute a robust barrier, constant representa-
tion of antigens of the commensal flora to the peripheral 
T-cell pool occurs  [19] . Landmark studies by Powrie et al. 
 [20] and others showed that the T-cell repertoire includes 
specificities that can facilitate inflammatory responses to 
the microbiota. Transferring this cell type into immuno-
deficient mice depleted of endogenous regulatory cells re-
sulted in the development of features of IBD.
 There are currently three described subsets of effector 
CD4+ T cells: Th1, Th2, and Th17 cells, all of which are 
also found in CD or UC, respectively. Differentiation into 
one of these cell subtypes is driven by cytokines mostly 
released from cells of the innate immune response. Ad-
ditionally, interconversion between various subsets has 
been proposed  [21] . Th1 response was originally associ-
ated with CD and starts with activation of STAT1 and 
STAT4 by IL-12 and interferons  [22] . The specific tran-
scription factor for the Th1 cells is T-bet, surface markers 
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include CCR1 and -5 and CXCR3  [23, 24] . A Th17-cell 
response is activated for example upon detection of extra-
cellular bacteria and fungi. The differentiation is induced 
by proinflammatory IL-6, IL-23 and TGF-β via STAT3 
and RORγT  [25] . IL-23, which shares the p40 subunit 
with IL-12, has been proposed as a key factor in experi-
mental models of CD  [26] . IL-17A and IL-17F are Th17 
cytokines and involved in neutrophil recruitment and ac-
tivation  [27] . Th17 cells have also been associated with 
CD. UC, on the other hand, is connected to a modified 
Th2 response associated with IL-5 and IL-13 responses 
that results in the specific activation of transcription fac-
tor GATA3  [28] . Th2 cells express CCR3 and -4 as surface 
markers. Effector T cells are the target of several clini-
cally effective therapies. For instance, it was shown in 
 patients with IBD that therapeutic anti-TNF antibodies 
induce T-cell apoptosis, when co-cultured with CD14+ 
macrophages  [29] . Recently, an additional T-cell pool 
moved into the focus of IBD pathogenesis. IL-33, a cyto-
kine of the IL-1 family, IL-23 and IL-25 are able to expand 
so-called innate lymphoid cells (ILCs). While these cells 
show normal lymphocyte morphology, they lack antigen 
receptors derived from rearrangement. Different subsets 
of ILCs have been proposed including NK cells, RORγT-
dependent ILC and RORα-dependent ILC2 and others. 
ILCs secrete IL-5, IL-9 and IL-13 and seem to play a role 
in IBD as well as tissue fibrosis, infection and allergic re-
action  [30–32] .
 The role of B cells IBD is only poorly examined and 
understood. This cell type primarily resides in the lym-
phoid follicles of the gastrointestinal tract and as plasma 
cells in the stroma of the lamina propria. IgA and IgM are 
constantly secreted by intestinal B cells and an important 
component of the epithelial barrier  [33] . In IBD, a re-
duced expression secretory IgA by dysfunctional B cells 
can be found  [34] . Furthermore, anti-epithelial cell auto-
antibodies have been proposed in UC, highlighting the 
potential role of B cells in these patients  [35] . It was also 
shown that peripheral blood B cells constitutively secrete 
proinflammatory IL-8 in patients with CD. This IL-8 pro-
duction by peripheral B cells correlated directly with dis-
ease severity (fig. 1)  [36] .
 In summary, cells of the innate and the adaptive im-
mune system have been identified as the key regulators of 
IBD. The innate immune system initiates an exaggerated 
inflammatory response and cells of the adaptive immune 
system contribute to the preservation of this pathologic 
condition. Using new tools, such as next-generation se-
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quencing  [37] techniques or new imaging technologies 
 [38], could help to gain an even better understanding of 
the underlying pathophysiology of CD and UC and con-
tribute to the identification of new therapeutic targets.
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